Cardiomyopathy: Clinical Management & Evidence Updates
Cardiomyopathy management requires nuanced understanding of disease heterogeneity, genetic architecture, and evolving therapeutic options. This resource equips healthcare professionals with evidence-based clinical guidance, specialist perspectives, and practice-changing insights across all cardiomyopathy phenotypes.
Clinical Focus Areas:
- Hypertrophic Cardiomyopathy (HCM) – Risk stratification and sudden cardiac death prevention, emerging cardiac myosin inhibitors (aficamten, mavacamten), ICD therapy decision-making, and genetic counseling protocols
- ATTR Cardiomyopathy – Novel disease-modifying therapies (TTR stabilizers, silencers, CRISPR gene editing), advanced cardiac imaging with CMR and nuclear scintigraphy, AI-enhanced diagnostic screening, and wild-type versus hereditary disease management
- Dilated Cardiomyopathy (DCM) – Precision medicine approaches targeting genetic variants (MYH7, TTN), family screening and cascade genetic testing, doxorubicin cardiotoxicity monitoring with multimodal imaging, and contemporary heart failure optimization
- Restrictive & Arrhythmogenic Cardiomyopathy – Diagnostic differentiation strategies, arrhythmia risk assessment and management, and specialized longitudinal follow-up protocols
- Diagnostic Pathways & Classification – Implementation of ESC and AHA/ACC guidelines, multimodal cardiac imaging interpretation (echocardiography, CMR with late gadolinium enhancement, cardiac PET/MRI, 99mTc-DPD scintigraphy), and genetic testing algorithms
Access peer-reviewed articles from Cardiac Failure Review, Arrhythmia & Electrophysiology Review, US Cardiology Review, and Journal of Asian Pacific Society of Cardiology, alongside expert clinical commentary, guideline analysis, case-based webinars, and conference coverage.
For cardiologists, internal medicine specialists, primary care physicians, cardiac nurses, genetic counselors, and allied healthcare professionals.
